болезнь Фабриболезни накоплениялизомальные болезниХ-сцепленная лизосомальная болезньглоботри- аозилцерамидGL-3Gb3гликосфинголипидыкардиомиопатияпочечная недостаточностьмикроальбуминурияферменто- заместительная терапия1.1. Desnick R., Ionnou Y., Eng C. Fabry disease: alpha galactosidase A deficiency. In: The metabolic and molecular bases of inherited disease. Ed. by Scriver C., Beaudet A., Sly W., Valle D., New York, McGraw-Hill, 1995, pp. 2741– 2784.Desnick R., Ionnou Y., Eng C. Fabry disease: alpha galactosidase A deficiency. In: The metabolic and molecular bases of inherited disease. Ed. by Scriver C., Beaudet A., Sly W., Valle D., New York, McGraw-Hill, 1995, pp. 2741– 2784.2.2. Zarate Y.A., Hopkin R.J. Fabry’s disease. Lancet 2008;372:1427–35.Zarate Y.A., Hopkin R.J. Fabry’s disease. Lancet 2008;372:1427–35.3.3. Desnick R.J., Brady R., Barranger J. et al. Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338–46.Desnick R.J., Brady R., Barranger J. et al. Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338–46.4.4. Banikazemi M., Bultas J., Waldek S. et al. Fabry Disease Clinical Trial Study Group: Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 2007;146:77–86.Banikazemi M., Bultas J., Waldek S. et al. Fabry Disease Clinical Trial Study Group: Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 2007;146:77–86.5.5. Eng C.M., Guffon N., Wilcox W.R. et al. International Collaborative FabryDisease Study Group: Safety and efficacy of recombinant human alpha-galactosidase A – replacement therapy in Fabry’s disease. N Engl J Med 2001;345:9–16.Eng C.M., Guffon N., Wilcox W.R. et al. International Collaborative FabryDisease Study Group: Safety and efficacy of recombinant human alpha-galactosidase A – replacement therapy in Fabry’s disease. N Engl J Med 2001;345:9–16.6.6. Hughes D.A., Elliott P.M., Shah J. et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebocontrolled clinical trial of agalsidase alfa. Heart 2008;94:153–8.Hughes D.A., Elliott P.M., Shah J. et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebocontrolled clinical trial of agalsidase alfa. Heart 2008;94:153–8.7.7. Mehta A., Beck M., Elliott P. et al. Fabry Outcome Survey investigators: Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: An analysis of registry data. Lancet 2009;374:1986–96.Mehta A., Beck M., Elliott P. et al. Fabry Outcome Survey investigators: Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: An analysis of registry data. Lancet 2009;374:1986–96.8.8. Schiffmann R., Kopp J.B., Austin H.A. 3rd et al. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 2001;285:2743–9.Schiffmann R., Kopp J.B., Austin H.A. 3rd et al. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 2001;285:2743–9.9.9. Wraith J.E., Tylki-Szymanska A., Guffon N. et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: An international, open-label study in pediatric patients with Fabry disease. J Pediatr 2008;152:563–70.Wraith J.E., Tylki-Szymanska A., Guffon N. et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: An international, open-label study in pediatric patients with Fabry disease. J Pediatr 2008;152:563–70.10.10. Tsuboi K., Yamamoto H. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). Genet Med 2012;14:779–86.Tsuboi K., Yamamoto H. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). Genet Med 2012;14:779–86.11.11. Linthorst G.E., Germain D.P., Hollak C.E. et al. European Medicines Agency: Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab 2011;102:99–102.Linthorst G.E., Germain D.P., Hollak C.E. et al. European Medicines Agency: Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab 2011;102:99–102.12.12. Pisani A., Spinelli L., Visciano B. et al. Effects of switching from agalsidase Betato agalsidase alfa in 10 patients with andersonfabry disease. JIMD Rep 2013;9:41–8.Pisani A., Spinelli L., Visciano B. et al. Effects of switching from agalsidase Betato agalsidase alfa in 10 patients with andersonfabry disease. JIMD Rep 2013;9:41–8.13.13. Smid B.E., Rombach S.M., Aerts J.M. et al. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis 2011;6:69.Smid B.E., Rombach S.M., Aerts J.M. et al. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis 2011;6:69.14.14. Weidemann F., Breunig F., Beer M. et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study. Circulation 2003;108:1299–301.Weidemann F., Breunig F., Beer M. et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study. Circulation 2003;108:1299–301.15.15. Weidemann F., Niemann M., Breunig F. et al. Long-termeffects of enzyme replacement therapy on fabry cardiomyopathy: Evidence for a better outcome with early treatment. Circulation 2009;119:524–9.Weidemann F., Niemann M., Breunig F. et al. Long-termeffects of enzyme replacement therapy on fabry cardiomyopathy: Evidence for a better outcome with early treatment. Circulation 2009;119:524–9.16.16. Feriozzi S., Torras J., Cybulla M. et al. FOS Investigators: The effectiveness of longterm agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol 2012;7:60–9.Feriozzi S., Torras J., Cybulla M. et al. FOS Investigators: The effectiveness of longterm agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol 2012;7:60–9.17.17. Germain D.P., Waldek S., Banikazemi M. et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007;18:1547–57.Germain D.P., Waldek S., Banikazemi M. et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007;18:1547–57.18.18. West M., Nicholls K., Mehta A. et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009;20:1132–9.West M., Nicholls K., Mehta A. et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009;20:1132–9.19.19. Najafian B., Svarstad E., Bostad L. et al. Progressive podocyte injury and globotriao sylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int 2011;79:663–70.Najafian B., Svarstad E., Bostad L. et al. Progressive podocyte injury and globotriao sylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int 2011;79:663–70.20.20. Gansevoort R.T., de Jong P.E. The case for using albuminuria in staging chronic kidney disease. J Am Soc Nephrol 2009;20:465–8.Gansevoort R.T., de Jong P.E. The case for using albuminuria in staging chronic kidney disease. J Am Soc Nephrol 2009;20:465–8.21.21. Miettinen H., Haffner S.M., Lehto S. et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996;27:2033–9.Miettinen H., Haffner S.M., Lehto S. et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996;27:2033–9.22.22. de Zeeuw D., Parving H.H., Henning R.H. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006;17:2100–5.de Zeeuw D., Parving H.H., Henning R.H. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006;17:2100–5.23.23. Linthorst G.E., Hollak C.E., Donker-Koopman W.E. et al. Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004;66:1589–95.Linthorst G.E., Hollak C.E., Donker-Koopman W.E. et al. Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004;66:1589–95.24.24. Tanaka A., Takeda T., Hoshina T. et al. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha. J Inherit Metab Dis 2010;33 (Suppl 3):249–52.Tanaka A., Takeda T., Hoshina T. et al. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha. J Inherit Metab Dis 2010;33 (Suppl 3):249–52.25.25. Helal I., Fick-Brosnahan G.M., Reed-Gitomer B., Schrier R.W. Glomerular hyperfiltration: Definitions, mechanisms and clinical implications. Nat Rev Nephrol 2012;8:293–300.Helal I., Fick-Brosnahan G.M., Reed-Gitomer B., Schrier R.W. Glomerular hyperfiltration: Definitions, mechanisms and clinical implications. Nat Rev Nephrol 2012;8:293–300.26.26. Levey A.S., Stevens L.A., Schmid C.H. et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–12.Levey A.S., Stevens L.A., Schmid C.H. et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–12.27.27. Von Korff M., Ormel J., Keefe F.J., Dworkin S.F. Grading the severity of chronic pain. Pain 1992;50:133–49.Von Korff M., Ormel J., Keefe F.J., Dworkin S.F. Grading the severity of chronic pain. Pain 1992;50:133–49.28.28. Sommer C., Richter H., Rogausch J.P. et al. A modified score to identify and discriminate neuropathic pain: A study on the German version of the Neuropathic Pain Symptom Inventory (NPSI). BMC Neurol 2011;11:104.Sommer C., Richter H., Rogausch J.P. et al. A modified score to identify and discriminate neuropathic pain: A study on the German version of the Neuropathic Pain Symptom Inventory (NPSI). BMC Neurol 2011;11:104.29.29. Rolke R., Baron R., Maier C. et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values. Pain 2006;123:231–43.Rolke R., Baron R., Maier C. et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values. Pain 2006;123:231–43.30.30. Fukuda K., Straus S.E., Hickie I. et al. International Chronic Fatigue Syndrome Study Group: The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann Intern Med 1994;121:953–9.Fukuda K., Straus S.E., Hickie I. et al. International Chronic Fatigue Syndrome Study Group: The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann Intern Med 1994;121:953–9.31.31. Giannini E.H., Mehta A.B , Hilz M.J. et al. A validated disease severity scoring system for Fabry disease. Mol Genet Metab 2010;99:283–90.Giannini E.H., Mehta A.B , Hilz M.J. et al. A validated disease severity scoring system for Fabry disease. Mol Genet Metab 2010;99:283–90.32.32. Whybra C., Kampmann C., Krummenauer F. et al. Severity Score Index: A new instrument for quantifying the Anderson- Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004;65:299–307.Whybra C., Kampmann C., Krummenauer F. et al. Severity Score Index: A new instrument for quantifying the Anderson- Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004;65:299–307.